CD080524127 Vimlesh 7bb8

Name : MR. VIMLESH Patient UID.
: P48143946
Visit No. : CD080524127 Registered on : 08/05/2024 16:12
Age/Gender : 54 Y / Male Collected on : 08/05/2024 16:12
Referred Client : NORTHERN RAILWAY HEALTH UNIT Approved on : 08/05/2024 17:00
Referred by : N/A Barcode No : 080524127
Doctor Name : FARIDABAD
CLINICAL BIOCHEMISTRY
Test Name Results Units Bio. Ref. Interval
CALCIUM - SERUM 8.8 mg/dL 8.4 - 10.2
Methodology : Arsenazo dye
Interpretation Notes :
A blood calcium test is ordered to screen for, diagnose, and monitor a range of conditions relating to the bones, heart, nerves, kidneys, and teeth. The test may also be ordered if
a person has symptoms of a parathyroid disorder, malabsorption, or an overactive thyroid.A total calcium level is often measured as part of a routine health screening. It is
included in the comprehensive metabolic panel (CMP) and the basic metabolic panel (BMP), groups of tests that are performed together to diagnose or monitor a variety of
conditions.When an abnormal total calcium result is obtained, it is viewed as an indicator of an underlying problem. To help diagnose the underlying problem, additional tests
are often done to measure ionized calcium, urine calcium, phosphorus, magnesium, vitamin D, parathyroid hormone (PTH) and PTH-related peptide (PTHrP). PTH and vitamin
D are responsible for maintaining calcium concentrations in the blood within a narrow range of values.If the calcium is abnormal, measuring calcium and PTH together can help
determine whether the parathyroid glands are functioning normally. Measuring urine calcium can help determine whether the kidneys are excreting the proper amount of
calcium, and testing for vitamin D, phosphorus, and/or magnesium can help determine whether other deficiencies or excesses exist. Frequently, the balance among these
different substances (and the changes in them) is just as important as the concentrations.
TOTAL CHOLESTEROL 182 mg/dL Desirable cholesterol : < 200

Borderline high cholesterol :
200 - 239
High cholesterol : >/= 240
Methodology : Enzymatic(CHE/CHO/POD)
The test for total cholesterol is used alone or as part of a lipid profile to help predict an individual's risk of developing heart disease and to help make decisions about what
treatment may be needed if there is borderline or high risk. As part of a lipid profile (which includes other tests for high-density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), and triglycerides), it may also be used to monitor the effectiveness of treatment once it is initiated.Because high blood cholesterol has been
associated with hardening of the arteries (atherosclerosis), heart disease, and a raised risk of death from heart attacks, cholesterol testing is considered a routine part of
preventive healthcare.Results of the cholesterol test and other components of the lipid profile are used along with other known risk factors of heart disease to develop a plan of
treatment and follow-up. Treatment options may include lifestyle changes such as diet or exercise programs or lipid-lowering drugs such as statins.
Primary Sample Type : SERUM
DR. PANKAJ TAYAL

M.B.B.S. DNB (PATH.)
Page 1 of 9 Consultant Pathologist
Name : MR. VIMLESH Patient UID. : P48143946
LIVER FUNCTION TEST.
TOTAL BILIRUBIN 0.20 mg/dL 0.2 - 1.3

Methodology : Azobilirubin/Dyphyllime
DIRECT BILIRUBIN 0.09 mg/dL <0.3
Methodology : Calculated
INDIRECT BILIRUBIN 0.11 mg/dL 0 - 0.6
Methodology : Spectrophotometry
SGOT (AST) 43 U/L <35
Methodology : Kinetic with Pyridoxal 5 Phosphate
SGPT (ALT) 34 U/L <45
Methodology : Kinetic with Pyridoxal 5 Phosphate
ALKALINE PHOSPHATASE (ALP) 70 U/L 38 - 126
Methodology : Para nitrophenyl phosphate, AMP buffer
Interpretation:
A liver panel may be used to screen for liver damage, especially if someone has a condition or is taking medications that may affect the liver. This group of tests includes most
of the liver panel as well as additional tests that evaluate other organs and systems within the body. If a person has a known condition or liver disease, testing may be performed
at intervals to monitor the health of the liver and to evaluate the effectiveness of any treatments. A series of bilirubin tests, for instance, may be ordered to evaluate and monitor a
jaundiced newborn. Abnormal tests on a liver panel may prompt a repeat analysis of one or more tests, or of the whole panel, to see if the elevations or decreases persist and/or
may indicate the need for additional testing to determine the cause of the liver dysfunction.
DR. PANKAJ TAYAL

KIDNEY FUNCTION TEST..
BLOOD UREA 17.9 mg/dL 19 - 43

Methodology : Urease with indicator dye
SERUM CREATININE 0.7 mg/dL 0.6 - 1.2
Methodology : Enzymatic(creatinine amidohydrolase)
URIC ACID - SERUM 5.7 mg/dL 3.5 - 8.5
Methodology : URICASE POD
SODIUM - SERUM 139 mmol/L 136 - 145
Methodology : ISE-DIRECT
POTASSIUM - SERUM 5.4 mmol/L 3.5 - 5.1
CHLORIDE - SERUM 104 mmol/L 98 - 107
DR. PANKAJ TAYAL

CLINICAL PATHOLOGY
URINE ROUTINE EXAMINATION ; URINE, R/E
PHYSICAL EXAMINATION
Urine colour PALE YELLOW
Urine Appearance Clear
CHEMICAL EXAMINATION
Urine pH 5.0 5.0 - 7.0
Specific Gravity 1.010 1.005 - 1.030
Urine Protein NIL NIL
Urine Glucose NIL NIL
MICROSCOPIC EXAMINATION
Urine Pus Cells 0-1 /HPF 0 - 5/HPF
Epithelial Cells Occasional /HPF 0 - 5/HPF
Urine RBC cells NIL /HPF NIL/HPF
Casts NIL NIL / LPF
Crystals NIL NIL/HPF
Bacteria NIL NIL/HPF
Other NIL
Primary Sample Type : URINE
DR. PANKAJ TAYAL

HAEMATOLOGY
GLYCOSYLATED HAEMOGLOBIN ( HbA1c )
GLYCOSYLATED HAEMOGLOBIN (%) 5.3 % Non diabetic level : <=5.6
Risk of diabetes : 5.7 - 6.4
Diabetes : >= 6.5
Methodology : HPLC
GLYCOSYLATED HAEMOGLOBIN (IFCC) 34 mmol / mol Normal < 37
Diabetic > 48
ESTIMATED AVERAGE GLUCOSE (eAG) 105.41 mg/dL
ESTIMATED AVERAGE GLUCOSE (3 MONTHS) 5.86 mmol/L 5.5 - 7.9
In vitro quantitative determination of HbA1c in whole blood is utilized in long term monitoring of glycemia.The HbA1c level correlates with the mean glucose concentration
prevailing in the course of the patient's recent history (approx - 6-8 weeks) and therefore provides much more reliable information for glycemia monitoring than do
determinations of blood glucose or urinary glucose. It is recommended that the determination of HbA1c be performed at intervals of 4-6 weeks during Diabetes Mellitus
therapy. Results of HbA1c should be assessed in conjunction with the patient's medical history, clinical examinations and other findings.
Good Control. : < 6.1 - 7.0 ; Marginal Control : 7.1 - 8.0 ; Poor Control. : > 8.1
Note: If variant hemoglobin is observed in HbA1c HPLC screen, HbA1c levels may not truly represent in vivo condition. In such condition HbA1c analysis by HPLC may not
be the method of choice. You are advised to consult your referring physician and discuss the alternative tests as suggested below. Advised: 1.To follow patient for glycemic
control test like fructosamine or glycated albumin may be performed instead. 2.Hemoglobin HPLC screen to analyze abnormal hemoglobin variant. Estimated Average
Glucose (eAG) : estimated Average Glucose (eAG) based on value calculated according to National Glycohemoglobin Standardization Program (NGSP) criteria. Disclaimer :
Test processed in referral lab.
Primary Sample Type : WHOLE BLOOD-EDTA
DR.NEETA SETH
M.B.B.S, MD (PATH.)
Page 5 of 9 SENIOR PATHOLOGIST
HAEMATOLOGY
COMPLETE BLOOD COUNT (CBC)
HAEMOGLOBIN (Hb) 13.6 g/dl 13 - 17

Methodology : Non-cyanide/ colorimetric
TOTAL LEUCOCYTE COUNT (TLC) 6.58 10^3/µL 4 - 10
Methodology : Flow Cytometry
PLATELET COUNT (PC) 218 10^3/µL 150 - 410
Methodology : Electrical Impedance/Microscopy
DIFFERENTIAL LEUCOCYTE COUNT (DLC)
Neutrophils 60 % 40 - 80
Methodology : Flow Cytometry/Microscopy
Lymphocytes 31 % 20 - 40
Eosinophils 07 % 1-6
Monocytes 02 % 2 - 10
Basophils 00 % 0-2
RED BLOOD CELL COUNT (RBC) 4.75 10^6 /µL 4.5 - 5.5
Methodology : Electrical Impedence
PACKED CELL VOLUME/HEMATOCRIT (PCV) 41.2 % 40 - 50
MEAN CORPUSCULAR VOLUME (MCV) 86.74 fL 83 - 101
MEAN CORPUSCULAR HAEMOGLOBIN (MCH) 28.63 pg 27 - 32
MCH CONCENTRATION (MCHC) 33.01 g/dl 31.5 - 34.5
DR. PANKAJ TAYAL

HAEMATOLOGY
COMPLETE BLOOD COUNT (CBC)
RED CELL DISTRIBUTION WIDTH (RDW-CV) 12.9 % 11 - 16.7

DR. PANKAJ TAYAL

IMMUNOLOGY
VITAMIN D, 25 HYDROXY 9.99 ng/mL Deficiency - < 20
Insufficiency - 20- <30
Sufficiency. - 30-100
Toxicity - >100
Methodology : ECLIA
Vitamin D is a family of compounds that is essential for the proper growth and formation of teeth and bones. This test measures the level of vitamin D in the
blood. Two forms of vitamin D can be measured in the blood, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. The 25-hydroxyvitamin D is the major form
found in the blood and is the relatively inactive precursor to the active hormone, 1,25-dihydroxyvitamin D. Because of its long half-life and higher concentration,
25-hydroxyvitamin D is commonly measured to assess and monitor vitamin D status in individuals. A vitamin D test is used to:Determine if bone weakness, bone
malformation, or abnormal metabolism of calcium (reflected by abnormal calcium, phosphorus, PTH) is occurring as a result of a deficiency or excess of vitamin
DHelp diagnose or monitor problems with parathyroid gland functioning since PTH is essential for vitamin D activationScreen people who are at high risk of
deficiency, as recommended by the National Osteoporosis Foundation, the Institute of Medicine, and the Endocrine SocietyHelp monitor the health status of
individuals with diseases that interfere with fat absorption, such as cystic fibrosis and Crohn disease, since vitamin D is a fat-soluble vitamin and is absorbed
from the intestine like a fatMonitor people who have had gastric bypass surgery and may not be able to absorb enough vitamin DHelp determine the
effectiveness of treatment when vitamin D, calcium, phosphorus, and/or magnesium supplementation is prescribed.
DR.NEETA SETH
M.B.B.S, MD (PATH.)
IMMUNOLOGY
THYROID STIMULATING HORMONE (TSH) 1.5 uIU/mL 0.46 - 4.68
Pregnancy
First trimester : 0.30 - 4.50
Second trimester : 0.50 - 4.60
Third trimester : 0.80 - 5.20
Methodology : ECLIA
The thyroid-stimulating hormone (TSH) test is often the test of choice for evaluating thyroid function and/or symptoms of a thyroid disorder, including hyperthyroidism or
hypothyroidism.TSH is produced by the pituitary gland, a tiny organ located below the brain and behind the sinus cavities. It is part of the body's feedback system to maintain
stable amounts of the thyroid hormones thyroxine (T4) and triiodothyronine (T3) in the blood and to help control the rate at which the body uses energy.A TSH test is frequently
ordered along with or preceding a free T4 test. Other thyroid tests that may be ordered include a free T3 test and thyroid antibodies (if autoimmune-related thyroid disease is
suspected). Sometimes TSH, free T4 and free T3 are ordered together as a thyroid panel.
*** End of Report ***

All tests have technical limitations.Collaborative clicnicopathological interpretation is mandatory. Isolated lab investigation may not confirm diagnosis of
disease. In case of Unexpected/alarming results,doctor/patient is advised to contact lab immediately for necessary action.
Processed By: RAJ

Verified by : DR.NEETA SETH
DR.NEETA SETH
M.B.B.S, MD (PATH.)

CD080524127 Vimlesh 7bb8

Uploaded by

Copyright:

Available Formats

CD080524127 Vimlesh 7bb8

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

CD080524127 Vimlesh 7bb8

Uploaded by

Copyright:

Available Formats

Name : MR. VIMLESH Patient UID.

TOTAL CHOLESTEROL 182 mg/dL Desirable cholesterol : < 200

Primary Sample Type : SERUM

DR. PANKAJ TAYAL

TOTAL BILIRUBIN 0.20 mg/dL 0.2 - 1.3

Primary Sample Type : SERUM

DR. PANKAJ TAYAL

BLOOD UREA 17.9 mg/dL 19 - 43

Primary Sample Type : SERUM

DR. PANKAJ TAYAL

Primary Sample Type : URINE

DR. PANKAJ TAYAL

Primary Sample Type : WHOLE BLOOD-EDTA

HAEMOGLOBIN (Hb) 13.6 g/dl 13 - 17

Primary Sample Type : WHOLE BLOOD-EDTA

DR. PANKAJ TAYAL

RED CELL DISTRIBUTION WIDTH (RDW-CV) 12.9 % 11 - 16.7

Primary Sample Type : WHOLE BLOOD-EDTA

DR. PANKAJ TAYAL

Primary Sample Type : SERUM

Primary Sample Type : SERUM

*** End of Report ***

Processed By: RAJ

You might also like

* End of Report *